Summary:
2021-PT055: Phase II, Double-Blind, Placebo-Controlled, Randomized Trial Examining Natrunix in Combination with Methotrexate for the Treatment of Rheumatoid Arthritis
INCLUSION CRITERIA:
-pts 18+
-must be MTX-inadequate responders
-has > or = 6/68 swollen/tender joints
-must be receiving 15-25 mg MTX/week for a minimum of 4 weeks
EXCLUSION CRITERIA:
-any prior exposure to Natrunix
-no biologics within 8 weeks prior to randomization
-no JAKi within 4 weeks prior to randomization
-any concurrent autoimmune disease with the exception of Sjogren’s secondary to RA
Qualified Participants May Receive:
- Study treatment at no charge
- Diagnostic tests at no charge
- Study related medical care
- Compensation up to $900 for time and travel purposes